|Other Names||Endosialin, Tumor endothelial marker 1, CD248, CD248, CD164L1, TEM1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6756b was selected from the C-term region of human CD248. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May play a role in tumor angiogenesis.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Expressed in tumor endothelial cells but absent or barely detectable in normal endothelial cells. Expressed in metastatic lesions of the liver and during angiogenesis of corpus luteum formation and wound healing. Expressed in vascular endothelial cells of malignant tumors but not in normal blood vessels. Expressed in stromal fibroblasts|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CD248 is believed to play a role in tumor angiogenesis. CD248 is being investigated as a potential target for cancer treatment.
Bagley,R.G., et.al., Microvasc. Res. 76 (3), 180-188 (2008)
If you have any additional inquiries please email technical services at email@example.com.